Top

Published in:

01-04-2012 | Valvular Heart Disease (V Nkomo, Section Editor)

Tricuspid Regurgitation: Pathophysiology and Management

Authors: Rashmi Thapa, Buddhadeb Dawn, Jayant Nath

Published in: Current Cardiology Reports | Issue 2/2012

Abstract

Tricuspid regurgitation (TR) is one of the most commonly encountered valvular problems in clinical practice. Although diagnosed easily with echocardiography, it contributes to significant mortality and morbidity when severe. Once thought to be a benign functional valvular abnormality, TR has received more attention in recent years and different treatment options have emerged. However, there is no consensus regarding the superiority of one treatment approach over another. With the development of percutaneous atrioventricular valves, new horizons are open for exploration in the treatment of TR. Clinical indications of treatment are likely to change with increased use of left ventricular assist devices and increased survival of patients with poor right ventricular function. This review discusses the pathophysiology and management of TR along with newer treatment modalities currently under investigation.

Silver MD, Lam JH, Ranganathan N, et al. Morphology of the human tricuspid valve. Circulation. 1971;43(3):333–48.PubMed

Fukuda S, Saracino G, Matsumura Y, et al. Three-dimensional geometry of the tricuspid annulus in healthy subjects and in patients with functional tricuspid regurgitation: a real-time, 3-dimensional echocardiographic study. Circulation. 2006;114(suppl):I-492–8.CrossRef

Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999;83:897–902.PubMedCrossRef

Lavie CJ, Hebert K, Cassidy M. Prevalence and severity of Doppler-detected valvular regurgitation and estimation of right-sided cardiac pressures in patients with normal two dimensional echocardiograms. Chest. 1993;103:226–31.PubMedCrossRef

Klein AL, Burstow DJ, Tajik AJ, et al. Age-related prevalence of valvular regurgitation in normal subjects: a comprehensive color flow examination of 118 volunteers. J Am Soc Echocardiogr. 1990;3:54–63.PubMed

Nath J, Foster E, Heidenreich P. Impact of Tricuspid Regurgitation on Long-Term Survival. J Am Coll Cardiol. 2004;43(3):405–9.PubMedCrossRef

Lewis JF, Webber JD, Sutton LL, et al. Discordance in degree of right and left ventricular dilation in patients with dilated cardiomyopathy: recognition and clinical implications. J Am Coll Cardiol. 1993;21:649–54.PubMedCrossRef

Edwards WD. Embryology and pathologic features of Ebstein’s anomaly. Prog Pediatr Cadiol. 1993;2:5–15.CrossRef

Hagler DJ, Squarcia U, Cabalka AK, et al. Mechanism of tricuspid regurgitation in paramembranous ventricular septal defect. J Am Soc Echocardiogr. 2002;15(4):364–8.PubMedCrossRef

10.

Desai RV, Seghatol-Eslami F, Nabavizadeh F, et al. Unusual mechanism of tricuspid regurgitation in ventricular septal defect. Echocardiogr. 2011;28(2):E36–8.CrossRef

11.

Kim JB, Spevack DM, Tunick PA, et al. The effect of transvenous pacemaker and implantable cardioverter defibrillator lead placement on tricuspid valve function: an observational study. J Am Soc Echocardiogr. 2008;21:284–7.PubMedCrossRef

12.

Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2006;48:e1–e148.PubMedCrossRef

13.

Waller BF, Moriarty AT, Eble JN, et al. Etiology of pure tricuspid regurgitation based on anular circumference and leaflet area: analysis of 45 necropsy patients with clinical and morphologic evidence of pure tricuspid regurgitation. J Am Coll Cardiol. 1986;7:1063–74.PubMedCrossRef

14.

Waller BF, Howard J, Fess S. Pathology of tricuspid valve stenosis and pure tricuspid regurgitation—part III. Clin Cardiol. 1995;18:225–30.PubMedCrossRef

15.

Ubago JL, Figueroa A, Ochoteco A, et al. Analysis of the amount of tricuspid valve anular dilation required to produce functional tricuspid regurgitation. Am J Cardiol. 1983;52:155–8.PubMedCrossRef

16.

Fukuda S, Song JM, Gillinov AM, et al. Tricuspid valve tethering predicts residual tricuspid regurgitation after tricuspid annuloplasty. Circulation. 2005;111:975–9.PubMedCrossRef

17.

Mutlak D, Aronson D, Lessick J, et al. Functional tricuspid regurgitation in patients with pulmonary hypertension: is pulmonary artery pressure the only determinant of regurgitation severity? Chest. 2009;135:115–21.PubMedCrossRef

18.

Spinner EM, Shannon P, Buice D, et al. In vitro characterization of the mechanisms responsible for functional tricuspid regurgitation. Circulation. 2011;124(8):920–9.PubMedCrossRef

19.

Matsuyama K, Matsumoto M, Sugita T, et al. Predictors of residual tricuspid regurgitation after mitral valve surgery. Ann Thorac Surg. 2003;75:1826–8.PubMedCrossRef

20.

Song H, Kang DH, Kim JH, et al. Percutaneous mitral valvuloplasty versus surgical treatment in mitral stenosis with severe tricuspid regurgitation. Circulation. 2007;116(suppl I):I246–50.PubMed

21.

Kim HK, Kim YJ, Kim KI, et al. Impact of the maze operation combined with left-sided valve surgery on the change in tricuspid regurgitation over time. Circulation. 2005;112(Suppl I):I14–9.PubMed

22.

Najib MQ, Vinales KL, Vittala SS, et al. Predictors for the Development of Severe Tricuspid Regurgitation with Anatomically Normal Valve in Patients with Atrial Fibrillation. Echocardiography. 2011 Nov 8. [Epub ahead of print].

23.

Groves PH, Hall RJ. Late tricuspid regurgitation following mitral valve surgery. J Heart Valve Dis. 1992;1:80–6.PubMed

24.

Izumi C, Miyake M, Takahashi S, et al. Progression of Isolated Tricuspid Regurgitation Late After Left-Sided Valve Surgery. Circ J. 2011 Sep 23. [Epub ahead of print].

25.

Ruel M, Rubens FD, Masters RG, et al. Late incidence and predictors of persistent or recurrent heart failure in patients with mitral prosthetic valves. J Thorac Cardiovasc Surg. 2004;128:278–83.PubMedCrossRef

26.

Henein MY, O’Sullivan CA, Li W, et al. Evidence for rheumatic valve disease in patients with severe tricuspid regurgitation long after mitral valve surgery: the role of 3D echo reconstruction. J Heart Valve Dis. 2003;12:566–72.PubMed

27.

Mauro MD, Bivona A, Iacò AL, et al. Mitral valve surgery for functional mitral regurgitation: prognostic role of tricuspid regurgitation. Eur J Cardiothorac Surg. 2009;35:635–40.PubMedCrossRef

28.

Sagie A, Schwammenthal E, Newell JB, et al. Significant tricuspid regurgitation is a marker for adverse outcome in patients undergoing percutaneous balloon mitral valvuloplasty. J Am Coll Cardiol. 1994;24:696–702.PubMedCrossRef

29.

Topilsky Y, Tribouilloy C, Michelena HI, et al. Pathophysiology of tricuspid regurgitation: quantitative Doppler echocardiographic assessment of respiratory dependence. Circulation. 2010;122(15):1505–13.PubMedCrossRef

30.

Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for Evaluation of the Severity of Native Valvular Regurgitation with Two-dimensional and Doppler Echocardiography. Available at: http://www.asefiles.org/vavularregurg.pdf. Accessed November 2011.

31.

• Yang WI, Shim CY, Kang MK, et al. Vena contracta width as a predictor of adverse outcomes in patients with severe isolated tricuspid regurgitation. J Am Soc Echocardiogr. 2011 Sep;24(9):1013-9. This is one of the few studies that reveal the association of isolated TR with increased morbidity and mortality. Vena contracta width of greater than 7 mm has been shown as an independent prognostic indicator, thus emphasizing the role of echocardiography to quantify existing TR.PubMedCrossRef

32.

Anwar AM, Geleijnse ML, Ten Cate FJ, et al. Assessment of tricuspid valve annulus size, shape and function using real-time three-dimensional echocardiography. Interact Cardiovasc Thorac Surg. 2006;5(6):683–7.PubMedCrossRef

33.

Anwar AM, Soliman OI, Nemes A, et al. Value of assessment of tricuspid annulus: real-time three-dimensional echocardiography and magnetic resonance imaging. Int J Cardiovasc Imaging. 2007;23(6):701–5.PubMedCrossRef

34.

Brecker SJ, Gibbs JS, Fox KM, et al. Comparison of Doppler derived haemodynamic variables and simultaneous high fidelity pressure measurements in severe pulmonary hypertension. Br Heart J. 1994;72:384–9.PubMedCrossRef

35.

Sadeghi HM, Alborz H, Serry R, et al. Is the use of modified Bernoulli equation valid in estimating pulmonary artery pressures in patients with severely dilated tricuspid annulus? Presented at the 51th Annual Scientific Sessions of the American College of Cardiology (abstr). J Am Coll Cardiol. 2002;39(5 Suppl A):425A.CrossRef

36.

Lange R, De Simone R, Bauernschmitt R, et al. Tricuspid valve reconstruction, a treatment option in acute endocarditis. Eur J Cardiothorac Surg. 1996;10:320–6.PubMedCrossRef

37.

Sutlic Z, Schmid C, Borst HG. Repair of flail anterior leaflets of tricuspid and mitral valves by cusp remodeling. Ann Thorac Surg. 1990;50:927–30.PubMedCrossRef

38.

Choi JB, Kim HK, Yoon HS, et al. Partial annular placation for atrioventricular valve regurgitation. Ann Thorac Surg. 1995;59:891–5.PubMedCrossRef

39.

Braunwald NS, Ross Jr J, Morrow AG. Conservative management of tricuspid regurgitation in patients undergoing mitral valve replacement. Circulation. 1967;35:I63–9.PubMed

40.

Colombo T, Russo C, Ciliberto GR, et al. Tricuspid regurgitation secondary to mitral valve disease: tricuspid annulus function as guide to tricuspid valve repair. Cardiovasc Surg. 2001;9(4):369–77.PubMedCrossRef

41.

Dreyfus GD, Corbi PJ, Chan KM, et al. Secondary tricuspid regurgitation or dilatation: which should be the criteria for surgical repair? Ann Thorac Surg. 2005;79:127–32.PubMedCrossRef

42.

Tager R, Skudicky D, Mueller U, et al. Long-term follow-up of rheumatic patients undergoing left-sided valve replacement with tricuspid annuloplasty–validity of preoperative echocardiographic criteria in the decision to perform tricuspid annuloplasty. Am J Cardiol. 1998;81(8):1013–6.PubMedCrossRef

43.

Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007;28(2):230–68.PubMedCrossRef

44.

Giamberti A, Chessa M, Ballotta A, et al. Functional tricuspid valve regurgitation in adults with congenital heart disease: an emerging problem. J Heart Valve Dis. 2011;20(5):565–70.PubMed

45.

Yilmaz O, Suri RM, Dearani JA, et al. Functional tricuspid regurgitation at the time of mitral valve repair for degenerative leaflet prolapse: the case for a selective approach. J Thorac Cardiovasc Surg. 2011;142(3):608–13.PubMedCrossRef

46.

Calafiore AM, Gallina S, Iacò AL, et al. Mitral valve surgery for functional mitral regurgitation: should moderate-or-more tricuspid regurgitation be treated? A propensity score analysis. Ann Thorac Surg. 2009;87(3):698–703.PubMedCrossRef

47.

García Fuster R, Vázquez A, Peláez AG, et al. Factors for development of late significant tricuspid regurgitation after mitral valve replacement: the impact of subvalvular preservation. Eur J Cardiothorac Surg. 2011;39(6):866–74.PubMedCrossRef

48.

Sadeghi HM, Kimura BJ, Raisinghani A, et al. Does lowering pulmonary arterial pressure eliminate severe functional tricuspid regurgitation?: Insights from pulmonary thromboendarterectomy. J Am Coll Cardiol. 2004;44:126–32.PubMedCrossRef

49.

Menzel T, Kramm T, Wagner S, et al. Improvement of tricuspid regurgitation after pulmonary thromboendarterectomy. Ann Thorac Surg. 2002;73:756–61.PubMedCrossRef

50.

Carrier M, Pellerin M, Guertin MC, et al. Twenty-five years’ clinical experience with repair of tricuspid insufficiency. J Heart Valve Dis. 2004;13(6):952–6.PubMed

51.

Carrier M, Hébert Y, Pellerin M, et al. Tricuspid valve replacement: an analysis of 25 years of experience at a single center. Ann Thorac Surg. 2003;75(1):47–50.PubMedCrossRef

52.

Filsoufi F, Anyanwu AC, Salzberg SP, et al. Long-term outcomes of tricuspid valve replacement in the current era. Ann Thorac Surg. 2005;80:845–50.PubMedCrossRef

53.

Topilsky Y, Khanna AD, Oh JK, et al. Preoperative factors associated with adverse outcome after tricuspid valve replacement. Circulation. 2011;123(18):1929–39.PubMedCrossRef

54.

Singh SK, Tang GH, Maganti MD, et al. Midterm outcomes of tricuspid valve repair versus replacement for organic tricuspid disease. Ann Thorac Surg. 2006;82:1735–41.PubMedCrossRef

55.

Bernal JM, Morales D, Revuelta C, et al. Reoperations after tricuspid valve repair. J Thorac Cardiovasc Surg. 2005;130:498–503.PubMedCrossRef

56.

McCarthy PM, Bhudia SK, Rajeswaran J, et al. Tricuspid valve repair: durability and risk factors for failure. J Thorac Cardiovasc Surg. 2004;127:674–85.PubMedCrossRef

57.

Tang GH, David TE, Singh SK, et al. Tricuspid valve repair with an annuloplasty ring results in improved long-term outcomes. Circulation. 2006;114(suppl I):I-577–81.CrossRef

58.

Ghanta RK, Chen R, Narayanasamy N, et al. Suture bicuspidization of the tricuspid valve versus ring annuloplasty for repair of functional tricuspid regurgitation: midterm results of 237 consecutive patients. J Thorac Cardiovasc Surg. 2007;133:117–26.PubMedCrossRef

59.

Pfannmüller B, Doenst T, Eberhardt K, et al. Increased risk of dehiscence after tricuspid valve repair with rigid annuloplasty rings. J Thorac Cardiovasc Surg. 2011 Jul 26. [Epub ahead of print]

60.

Izutani H, Nakamura T, Kawachi K. Flexible band versus rigid ring annuloplasty for functional tricuspid regurgitation. Heart Int. 2010;5(2):e13.PubMedCrossRef

61.

Fukuda S, Gillinov AM, McCarthy PM, et al. Determinants of recurrent or residual functional tricuspid regurgitation after tricuspid annuloplasty. Circulation. 2006;114(suppl I):I-582–7.CrossRef

62.

Ghoreishi M, Brown JM, Stauffer CE, et al. Undersized tricuspid annuloplasty rings optimally treat functional tricuspid regurgitation. Ann Thorac Surg. 2011;92(1):89–95.PubMedCrossRef

63.

Alfieri O, De Bonis M, Lapenna E, et al. The “clover technique” as a novel approach for correction of post-traumatic tricuspid regurgitation. J Thorac Cardiovasc Surg. 2003;126(1):75–9.PubMedCrossRef

64.

De Bonis M, Lapenna E, La Canna G, et al. A novel technique for correction of severe tricuspid valve regurgitation due to complex lesions. Eur J Cardiothorac Surg. 2004;25(5):760–5.PubMedCrossRef

65.

Fayad G, Modine T, Ennezat PV, et al. The “clover technique” as a new approach for correction of postendocarditic severe tricuspid valve regurgitation. J Thorac Cardiovasc Surg. 2005;130(4):1208–10.PubMedCrossRef

66.

Hisata Y, Hazama S, Izumi K, et al. ‘Clover technique’ for tricuspid regurgitation due to pacemaker lead. J Heart Valve Dis. 2011;20(4):464–5.PubMed

67.

Castedo E, Canas A, Cabo RA, et al. Edge-to-Edge tricuspid repair for redeveloped valve incompetence after DeVega’s annuloplasty. Ann Thorac Surg. 2003;75:605–6.PubMedCrossRef

68.

Kaplan M, Kut M, Demirtas M, et al. Prosthetic replacement of the tricuspid valve: bioprosthetic or mechanical. Ann Thorac Surg. 2002;73:467–73.PubMedCrossRef

69.

Rizzoli G, Vendramin I, Nesseris G, et al. Biological or mechanical prosthesis in the tricuspid position? A meta-analysis of intra-institutional results. Ann Thorac Surg. 2004;77:1607–14.PubMedCrossRef

70.

Kunadian B, Vijayalakshmi K, Balasubramanian S, et al. Should the tricuspid valve be replaced with a mechanical or biological valve? Interact Cardiovasc Thorac Surg. 2007;6:551–7.PubMedCrossRef

71.

Boudjemline Y, Agnoletti G, Bonnet D, et al. Steps toward the percutaneous replacement of atrioventricular valves an experimental study. J Am Coll Cardiol. 2005;46:360–5.PubMedCrossRef

72.

Zegdi R, Khabbaz Z, Borenstein N, et al. A repositionable valved stent for endovascular treatment of deteriorated bioprostheses. J Am Coll Cardiol. 2006;48:1365–8.PubMedCrossRef

73.

•• Lauten A, Figulla HR, Willich C, et al. Heterotopic Valve Replacement as an Interventional Approach to Tricuspid Regurgitation. J Am Coll Cardiol. 2010;55:499–500. This is the first ever attempt in an animal study to treat TR using percutaneous valves in the SVC and IVC positions. The study showed improved cardiac output and hemodynamics.PubMedCrossRef

74.

Lauten A, Figulla HR, Willich C, et al. Percutaneous caval stent valve implantation: investigation of an interventional approach for treatment of tricuspid regurgitation. Eur Heart J. 2010;31(10):1274–81.PubMedCrossRef

75.

Corno AF, Zhou J, Tozzi P, et al. Off-bypass implantation of a self-expandable valved stent between inferior vena cava and right atrium. Interact Cardiovasc Thorac Surg. 2003;2:166–9.PubMedCrossRef

76.

Kenny D, Hijazi ZM, Walsh KP. Transcatheter tricuspid valve replacement with the Edwards SAPIEN valve. Catheter Cardiovasc Interv. 2011;78(2):267–70.PubMedCrossRef

77.

Webb JG, Wood DA, Ye J, et al. Transcatheter valve-in-valve implantation for failed bioprosthetic heart valves. Circulation. 2010;121(16):1848–57.PubMedCrossRef

78.

•• Roberts PA, Boudjemline Y, Cheatham JP, et al. Percutaneous Tricuspid Valve Replacement in Congenital and Acquired Heart Disease. J Am Coll Cardiol. 2011;58(2):117–122. This is one of the first data sets of patients undergoing percutaneous TV replacement with the Melody valve. Significant improvement was noted in TR or tricuspid stenosis.PubMedCrossRef

79.

• Maltais S, Topilsky Y, Tchantchaleishvili V, et al. Surgical treatment of tricuspid valve insufficiency promotes early reverse remodeling in patients with axial-flow left ventricular assist devices. J Thorac Cardiovasc Surg. 2011 Aug 10. [Epub ahead of print]. This is one of the few studies conducted in patients undergoing LVAD surgeries with concomitant surgery for severe TR. There was reduction in TR as well as reverse remodeling of the right ventricle.

80.

Krishan K, Nair A, Pinney S, et al. Liberal use of tricuspid-valve annuloplasty during left-ventricular assist device implantation. Eur J Cardiothorac Surg. 2011 Jul 5. [Epub ahead of print].

81.

Piacentino V 3^rd, Troupes CD, Ganapathi AM, et al. Clinical impact of concomitant tricuspid valve procedures during left ventricular assist device implantation. Ann Thorac Surg. 2011;92(4):1414–8. discussion 1418–9.PubMedCrossRef

82.

Potapov EV, Schweiger M, Stepanenko A, et al. Tricuspid valve repair in patients supported with left ventricular assist devices. ASAIO J. 2011;57(5):363–7.PubMedCrossRef

83.

Slaughter MS, Pagani FD, Rogers JG, et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant. 2010;29 suppl 4:S1–S39.PubMedCrossRef

84.

McCarthy JF, Cosgrove DM 3^rd. Tricuspid valve repair with the Cosgrove-Edwards Annuloplasty System. Ann Thorac Surg. 1997;64(1):267–8.PubMedCrossRef

85.

Kanter KR, Doelling NR, Fyfe DA, Sharma S, Tam VK. De Vega tricuspid annuloplasty for tricuspid regurgitation in children. Ann Thorac Surg. 2001;72(4):1344–8.PubMedCrossRef

Title: Tricuspid Regurgitation: Pathophysiology and Management
Authors: Rashmi Thapa
Buddhadeb Dawn
Jayant Nath
Publication date: 01-04-2012
Publisher: Current Science Inc.
Published in: Current Cardiology Reports / Issue 2/2012
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-012-0245-2

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tricuspid Regurgitation: Pathophysiology and Management

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Renal Intervention to Treat Hypertension

Management of Combined Severe Carotid and Coronary Artery Disease

Advances in Nuclear Cardiac Instrumentation with a View Towards Reduced Radiation Exposure

Molecular Imaging of Amyloidosis: Will the Heart Be the Next Target After the Brain?

The Potential Utility of 123I-mIBG in Atrial Fibrillation and in the Electrophysiology Laboratory

Multimodality Imaging for Assessment of Myocardial Viability: Nuclear, Echocardiography, MR, and CT

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page